Concepts (124)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epilepsy | 2 | 2020 | 64 | 1.240 |
Why?
|
| Seizures | 2 | 2020 | 65 | 1.220 |
Why?
|
| Amygdala | 9 | 2015 | 41 | 1.060 |
Why?
|
| Long-Term Potentiation | 7 | 2015 | 13 | 0.880 |
Why?
|
| Cocaine | 6 | 2011 | 31 | 0.630 |
Why?
|
| Body Temperature Regulation | 1 | 2018 | 20 | 0.590 |
Why?
|
| Hematoma, Subdural, Acute | 1 | 2017 | 7 | 0.550 |
Why?
|
| Dopamine Uptake Inhibitors | 4 | 2010 | 12 | 0.440 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 3 | 2006 | 5 | 0.400 |
Why?
|
| Synaptic Transmission | 5 | 2011 | 25 | 0.350 |
Why?
|
| Receptors, Metabotropic Glutamate | 3 | 2015 | 14 | 0.320 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 3 | 2011 | 26 | 0.300 |
Why?
|
| Corticotropin-Releasing Hormone | 4 | 2010 | 8 | 0.290 |
Why?
|
| Synapses | 2 | 2011 | 36 | 0.290 |
Why?
|
| Brain | 1 | 2017 | 1663 | 0.280 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2006 | 34 | 0.270 |
Why?
|
| Substance Withdrawal Syndrome | 4 | 2011 | 34 | 0.270 |
Why?
|
| Animals | 11 | 2018 | 3780 | 0.250 |
Why?
|
| Electroencephalography | 2 | 2017 | 80 | 0.250 |
Why?
|
| Rats | 9 | 2015 | 678 | 0.240 |
Why?
|
| Phospholipase D | 2 | 2015 | 5 | 0.220 |
Why?
|
| 8-Hydroxy-2-(di-n-propylamino)tetralin | 1 | 2003 | 3 | 0.210 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2003 | 4 | 0.210 |
Why?
|
| Receptors, Serotonin | 1 | 2003 | 13 | 0.210 |
Why?
|
| Rats, Sprague-Dawley | 8 | 2015 | 341 | 0.210 |
Why?
|
| Status Epilepticus | 1 | 2020 | 13 | 0.180 |
Why?
|
| Dopamine | 2 | 2011 | 87 | 0.160 |
Why?
|
| Behavior, Animal | 3 | 2011 | 45 | 0.140 |
Why?
|
| Anticonvulsants | 1 | 2017 | 57 | 0.130 |
Why?
|
| Reflex, Startle | 1 | 2015 | 4 | 0.130 |
Why?
|
| Child | 1 | 2020 | 1421 | 0.130 |
Why?
|
| Male | 11 | 2017 | 15269 | 0.130 |
Why?
|
| Fear | 1 | 2015 | 46 | 0.130 |
Why?
|
| Prefrontal Cortex | 2 | 2008 | 137 | 0.120 |
Why?
|
| Comorbidity | 1 | 2017 | 500 | 0.120 |
Why?
|
| Hematoma, Subdural | 1 | 2015 | 7 | 0.120 |
Why?
|
| Cortical Spreading Depression | 1 | 2014 | 1 | 0.120 |
Why?
|
| Humans | 6 | 2020 | 28395 | 0.120 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2011 | 28 | 0.120 |
Why?
|
| Lung Diseases | 1 | 2015 | 47 | 0.120 |
Why?
|
| Brain Injuries | 1 | 2014 | 36 | 0.110 |
Why?
|
| Incidence | 1 | 2017 | 773 | 0.110 |
Why?
|
| Respiration, Artificial | 1 | 2015 | 114 | 0.110 |
Why?
|
| In Vitro Techniques | 3 | 2010 | 176 | 0.100 |
Why?
|
| Adult | 3 | 2020 | 8097 | 0.100 |
Why?
|
| Neuronal Plasticity | 1 | 2011 | 47 | 0.090 |
Why?
|
| Drug Interactions | 2 | 2010 | 38 | 0.090 |
Why?
|
| Treatment Outcome | 2 | 2017 | 3615 | 0.090 |
Why?
|
| Receptors, Dopamine | 1 | 2010 | 8 | 0.090 |
Why?
|
| Retrospective Studies | 2 | 2017 | 3609 | 0.090 |
Why?
|
| Cocaine-Related Disorders | 2 | 2006 | 13 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2010 | 351 | 0.080 |
Why?
|
| Drug Administration Schedule | 2 | 2006 | 166 | 0.080 |
Why?
|
| Female | 4 | 2017 | 15704 | 0.080 |
Why?
|
| Aged | 3 | 2017 | 9256 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2015 | 931 | 0.070 |
Why?
|
| Excitatory Postsynaptic Potentials | 3 | 2015 | 6 | 0.070 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2006 | 2 | 0.070 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2006 | 15 | 0.070 |
Why?
|
| Electric Stimulation | 3 | 2015 | 53 | 0.070 |
Why?
|
| Glutamic Acid | 1 | 2006 | 25 | 0.070 |
Why?
|
| Enzyme Activation | 1 | 2006 | 120 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 120 | 0.060 |
Why?
|
| Tissue Culture Techniques | 1 | 2005 | 7 | 0.060 |
Why?
|
| Patch-Clamp Techniques | 3 | 2011 | 114 | 0.060 |
Why?
|
| Pyramidal Cells | 1 | 2005 | 34 | 0.060 |
Why?
|
| Cyclopropanes | 2 | 2015 | 15 | 0.060 |
Why?
|
| Glycine | 2 | 2015 | 12 | 0.060 |
Why?
|
| Receptors, Serotonin, 5-HT1 | 1 | 2003 | 1 | 0.050 |
Why?
|
| Serotonin Antagonists | 1 | 2003 | 8 | 0.050 |
Why?
|
| Rats, Wistar | 1 | 2003 | 52 | 0.050 |
Why?
|
| Neural Pathways | 2 | 2015 | 65 | 0.050 |
Why?
|
| Evoked Potentials | 2 | 2014 | 12 | 0.050 |
Why?
|
| Cues | 2 | 2011 | 43 | 0.040 |
Why?
|
| Dopamine Agents | 2 | 2010 | 16 | 0.040 |
Why?
|
| Young Adult | 2 | 2015 | 2069 | 0.040 |
Why?
|
| Memory, Long-Term | 1 | 2015 | 1 | 0.030 |
Why?
|
| Conditioning, Classical | 1 | 2015 | 4 | 0.030 |
Why?
|
| Fructose-Bisphosphate Aldolase | 1 | 2015 | 3 | 0.030 |
Why?
|
| Thalamus | 1 | 2015 | 16 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2010 | 619 | 0.030 |
Why?
|
| Survivors | 1 | 2015 | 71 | 0.030 |
Why?
|
| Ventilator Weaning | 1 | 2015 | 37 | 0.030 |
Why?
|
| Functional Laterality | 1 | 2014 | 62 | 0.030 |
Why?
|
| Time Factors | 2 | 2010 | 1490 | 0.030 |
Why?
|
| Intubation, Intratracheal | 1 | 2015 | 99 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2015 | 163 | 0.030 |
Why?
|
| Neurosurgical Procedures | 1 | 2015 | 127 | 0.030 |
Why?
|
| Radiography | 1 | 2015 | 639 | 0.030 |
Why?
|
| Length of Stay | 1 | 2015 | 328 | 0.030 |
Why?
|
| Critical Care | 1 | 2014 | 199 | 0.020 |
Why?
|
| Raclopride | 1 | 2011 | 1 | 0.020 |
Why?
|
| Receptors, Dopamine D5 | 1 | 2011 | 1 | 0.020 |
Why?
|
| Benzazepines | 1 | 2011 | 4 | 0.020 |
Why?
|
| Receptors, Dopamine D1 | 1 | 2011 | 6 | 0.020 |
Why?
|
| Picrotoxin | 1 | 2011 | 1 | 0.020 |
Why?
|
| Receptor, Cannabinoid, CB2 | 1 | 2011 | 1 | 0.020 |
Why?
|
| GABA Antagonists | 1 | 2011 | 2 | 0.020 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2011 | 2 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2011 | 53 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2011 | 34 | 0.020 |
Why?
|
| Receptor, Metabotropic Glutamate 5 | 1 | 2011 | 11 | 0.020 |
Why?
|
| Middle Aged | 2 | 2015 | 9250 | 0.020 |
Why?
|
| GABA Agents | 1 | 2010 | 1 | 0.020 |
Why?
|
| Excitatory Amino Acid Agents | 1 | 2010 | 1 | 0.020 |
Why?
|
| Models, Neurological | 1 | 2010 | 25 | 0.020 |
Why?
|
| Memory | 1 | 2011 | 302 | 0.020 |
Why?
|
| Adolescent | 1 | 2015 | 2307 | 0.020 |
Why?
|
| Guanosine Diphosphate | 1 | 2008 | 3 | 0.020 |
Why?
|
| Thionucleotides | 1 | 2008 | 4 | 0.020 |
Why?
|
| Inhibitory Postsynaptic Potentials | 1 | 2008 | 2 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2008 | 40 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2008 | 45 | 0.020 |
Why?
|
| Motor Activity | 1 | 2010 | 329 | 0.020 |
Why?
|
| Calcium Channels, L-Type | 1 | 2006 | 54 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2006 | 18 | 0.020 |
Why?
|
| Models, Biological | 1 | 2008 | 326 | 0.020 |
Why?
|
| Limbic System | 1 | 2005 | 8 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2006 | 59 | 0.020 |
Why?
|
| Neocortex | 1 | 2005 | 31 | 0.020 |
Why?
|
| Nerve Net | 1 | 2005 | 41 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 4851 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2006 | 441 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2005 | 539 | 0.010 |
Why?
|